New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
14:01 EDTOPKOPKO Health reports positive interim six-month Lagova Phase 2 data
OPKO Health announced 6 month results of a Phase 2 dose-finding study evaluating the safety and efficacy of its novel long-acting human growth hormone product to treat pediatric growth hormone deficiency disorder. All three Lagova once-weekly doses demonstrate strong catch-up growth during the six months treatment. The annualized growth rates are above 12 cm in all three doses. The results are supported by excellent dose dependent pharmacokinetics and pharmacodynamics profiles. Lagova shows a promising safety profile with no serious adverse events reported. Glucose and lipid metabolism markers are within the normal ranges. No lipoatrophy was observed in any patients dosed, and no clinically significant local tolerability issues were identified. “Based on these encouraging safety and efficacy results, OPKO plans to move aggressively into a single confirmatory pivotal Phase 3 study for pediatric GHD patients. We hope to make Lagova available to pediatric GHD patients as soon as possible,” said CEO, Phillip Frost, M.D. “Lagova is one of a family of important products being developed at OPKO Biologics designed to improve compliance and offer ease of administration to patients.”
News For OPK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
10:01 EDTOPKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:32 EDTOPKOPKO Health to present results of once-weekly dosing of hGH-CTP
Subscribe for More Information
08:17 EDTOPKOPKO Health downgraded at Oppenheimer
Subscribe for More Information
07:13 EDTOPKOPKO Health downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
March 2, 2015
11:52 EDTOPKOPKO Health price target raised to $18.50 from $14.50 at Ladenburg
Subscribe for More Information
February 27, 2015
17:36 EDTOPKOPKO Health says has adequate liquidity to continue product development
The company said, "We believe that OPKO’s cash and cash equivalents of $96.9 million at December 31, 2014, together with the $295.0 million in upfront payments from Pfizer received in 2015, provide OPKO with adequate liquidity to continue development of its product candidates."
17:33 EDTOPKOPKO Health reports Q4 EPS (12c), consensus (6c)
Subscribe for More Information
February 20, 2015
12:41 EDTOPKOPKO Health annouces publication of 20 year outcome study for prostate cancer
OPKO Health announced the online publication of a study entitled “Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study” in the journal European Urology. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore Test accurately identify men more likely to develop distant prostate cancer metastases, and men with a low 4Kscore were shown to have a low risk of developing metastatic prostate cancer in a 20-year follow up period. The study is part of the Västerbotten Intervention Project, which was initiated in 1986 in Västerbotten County, Sweden, and is a population-based study involving a health exam at ages 40, 50, and 60 years of age, where blood was drawn and preserved. The VIP study included data on over 40,000 men, representing greater than 57% of the total background population in Västerbotten County. From this cohort, blood samples of men who developed metastatic prostate cancer and age-matched controls of cancer free men were tested for the four kallikreins and their 4Kscore result was determined.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use